Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Emerging Trends in Inhaled Drug Delivery
share announcement

Emerging Trends in Inhaled Drug Delivery

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 28 May 2024 | Viewed by 1137

Special Issue Editor

Dr. Nitesh K. Kunda

E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Jamaica, NY, USA
Interests: inhaled drug delivery; thermostable vaccines; nanomedicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inhaled drug delivery is an excellent choice for non-invasive administration of drugs and has gained significant attention in the past decade or so. Pulmonary delivery allows for the direct administration of drugs/ biologics into the lungs for the treatment of both local and systemic diseases. The lungs, as a delivery site, offer many advantages such as a large surface area, dense vasculature, lower enzymatic activity than the gut, and a thin alveolar epithelium that allows for rapid absorption and immediate onset of action. The right combination of formulation and device is needed to generate particles or droplets of an appropriate aerodynamic diameter to achieve deposition in the respiratory airways. Recent advances in the field of pharmaceutical engineering, quality-by-design, and process analytical technology have enabled significant progress in formulation development for inhaled delivery.

In this Special Issue, we aim to collect articles that highlight and discuss the latest advances and emerging trends in inhaled drug delivery. Potential articles for this Special Issue may focus on the role of nanoparticles in pulmonary drug delivery, a quality-by-design-based approach toward the development of inhalable formulations, repurposing and reformulation of drugs and drug products for inhaled delivery, targeted delivery to specific regions of the lungs, and pulmonary vaccine delivery.

Dr. Nitesh K. Kunda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inhaled drug delivery
  • quality-by-design
  • nanoparticles in inhalation
  • pulmonary vaccine delivery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

12 pages, 487 KiB  
Review
Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics
by Ralph Brattsand and Olof Selroos
Pharmaceuticals 2024, 17(4), 503; https://doi.org/10.3390/ph17040503 - 15 Apr 2024
Viewed by 672
Abstract
The introduction of inhaled corticosteroids (ICSs) changed over a few decades the treatment focus of mild-to-moderate asthma from bronchodilation to reduction in inflammation. This was achieved by inhaling a suitable corticosteroid (CS), giving a high, protracted airway concentration at a low total dose, [...] Read more.
The introduction of inhaled corticosteroids (ICSs) changed over a few decades the treatment focus of mild-to-moderate asthma from bronchodilation to reduction in inflammation. This was achieved by inhaling a suitable corticosteroid (CS), giving a high, protracted airway concentration at a low total dose, thereby better combining efficacy and tolerance than oral therapy. Successful trials with the potent, lipophilic “skin” CS beclomethasone dipropionate (BDP) paved the way, suggesting that ICSs require a very low water solubility, prolonging their intraluminal dissolution within airways. The subsequent ICS development, with resulting clinical landmarks, is exemplified here with budesonide (BUD), showing that a similar efficacy/safety relationship is achievable by partly alternative mechanisms. BUD is much less lipophilic, giving it a 100-fold higher water solubility than BDP and later developed ICSs, leading to its more rapid intraluminal dissolution and faster airway and systemic uptake rates. In airway tissue, a BUD fraction is reversibly esterified to intracellular fatty acids, a lipophilic conjugate, which prolongs airway efficacy. Another mechanism is that the rapidly absorbed bulk fraction, via short plasma peaks, adds anti-inflammatory activity at the blood and bone marrow levels. Importantly, these plasma peaks are too short to provoke systemic adverse actions. Controlled clinical trials with BUD changed the use of ICS from a last resort to first-line treatment. Starting ICS treatment immediately after diagnosis (“early intervention”) became a landmark for BUD. An established dose response made BUD suitable for the treatment of patients with all degrees of asthma severity. With the development of the budesonide/formoterol combination inhaler (BUD/FORM), BUD contributed to the widely used BUD/FORM maintenance and reliever therapy (MART). Recent studies demonstrated the value of BUD/FORM as a generally recommended as-needed therapy for asthma (“anti-inflammatory reliever”, AIR). These abovementioned qualities have all influenced international asthma management and treatment guidelines. Full article
(This article belongs to the Special Issue Emerging Trends in Inhaled Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop